Clinical Trials /

Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

NCT03003468

Description:

This is an open label, multi-institutional, single arm study with a dose escalation phase Ib cohort, followed by a phase II cohort of pembrolizumab and Imprime PGG. No randomization or blinding is involved.

Related Conditions:
  • Non-Small Cell Lung Carcinoma
Recruiting Status:

Recruiting

Phase:

Phase 1/Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Chemotherapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
  • Official Title: A Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients With Metastatic Non-small Cell Lung Cancer After Progression on First-Line Chemotherapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

Clinical Trial IDs

  • ORG STUDY ID: BTCRC-LUN15-017
  • NCT ID: NCT03003468

Conditions

  • Non-Small Cell Lung Cancer

Interventions

DrugSynonymsArms
Imprime PGGArm A - Phase Ib
MK-3475pembrolizumabArm A - Phase Ib
Imprime PGGArm B - Phase II Investigational Treatment

Purpose

This is an open label, multi-institutional, single arm study with a dose escalation phase Ib cohort, followed by a phase II cohort of pembrolizumab and Imprime PGG. No randomization or blinding is involved.

Detailed Description

OUTLINE: This is a multi-center study.

The phase Ib dose escalation will evaluate the combination of pembrolizumab and Imprime PGG for subjects with metastatic non-small cell lung cancer (NSCLC) after progression on first-line platinum-based chemotherapy. The phase II trial will test whether addition of Imprime PGG to pembrolizumab will increase median progression-free survival (PFS) in second line therapy setting in NSCLC.

PHASE Ib DOSE ESCALATION INVESTIGATIONAL TREATMENT:

Cohort 1 will consist of 3-6 patients who will receive

- Imprime PGG 2 mg/kg IV on Days 1, 8, 15

- Pembrolizumab 200 mg IV on Day 1 (cycle = 21 days)

Cohort 2 will consist of 3-9 patients who will receive

- Imprime PGG 4 mg/kg IV on Days 1, 8, 15

- Pembrolizumab 200 mg IV on Day 1 (cycle = 21 days)

If none of the 3 subjects experience a dose limiting toxicity (DLT) during the first cycle of therapy, an additional three subjects will be enrolled at dose level 2. If all subjects in dose level 2 complete the first cycle of therapy without DLT, 3 more subjects will be enrolled into dose level 2 to ensure only 0-1 of 6 subjects have a DLT. There will be no further escalation beyond dose level 2.

PHASE II INVESTIGATIONAL TREATMENT:

Pembrolizumab will be given on Day 1 of each 21 day cycle after Imprime PGG, and the RP2D dose of Imprime PGG will be given on Days 1, 8 and 15 of each 21 day cycle. Treatment will continue up to 16 cycles, or until disease progression, unacceptable toxicity, subject refusal, or subject death either from progression of disease, the therapy itself, or from other causes.

Life expectancy: of 6 months or greater

The following baseline labs must be completed within 28 days prior to registration for protocol therapy:

Hepatic:

- total bilirubin ≤ 1.5 × upper limit of normal (ULN) OR direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 x ULN (except subject with Gilbert's Syndrome, who can have total bilirubin < 3.0 mg/dl)

- aspartate aminotransferase (AST) ≤ 2.5 × ULN or ≤ 5 × ULN for subjects with known hepatic metastases

- alanine aminotransferase (ALT) ≤ 2.5 × ULN or ≤ 5 × ULN for subjects with known hepatic metastases

Renal:

- Serum creatinine ≤ 3 mg/dL OR

- if serum creatinine > 3mg/dL, estimated glomerular filtration rate (GFR) ≥ 20 mL/min

Hematopoietic:

- hemoglobin ≥ 9 g/dL, subjects requiring transfusion will not be eligible to start study

- and absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L

- and platelet count ≥ 100 × 10^9/L

Coagulation:

- INR < 1.5 × ULN OR

- for subjects receiving anticoagulant, the subjects must, in the investigator's opinion, be clinically stable with no evidence of active bleeding while receiving anticoagulant therapy. The INR for subjects on warfarin should be in the therapeutic range. Low molecular weight heparin (LMWH) is allowed.

Trial Arms

NameTypeDescriptionInterventions
Arm A - Phase IbExperimentalDose Escalation Cohort Cohort 1 will consist of 3-6 patients who will receive pembrolizumab 200mg IV on Day 1 and Imprime PGG at 2mg/kg on Day 1,8, and 15 of each 21 day cycle. On Day 1 of each cycle, the Imprime PGG intravenous infusion is given first followed 15-30 minutes later by the pembrolizumab. Cohort 2 will consist of 3-6 patients who will receive pembrolizumab 200mg IV on Day 1 and Imprime PGG at 4mg/kg on Day 1,8, and 15 of each 21 day cycle. On Day 1 of each cycle, the Imprime PGG intravenous infusion is given first followed 15-30 minutes later by the pembrolizumab. If none of the 3 subjects experience a dose limiting toxicity (DLT) during the first cycle of therapy, an additional three subjects will be enrolled at dose level 2. If all subjects in dose level 2 complete the first cycle of therapy without DLT, 3 more subjects will be enrolled into dose level 2 to ensure only 0-1 of 6 subjects have a DLT. There will be no further escalation beyond dose level 2.
  • Imprime PGG
  • MK-3475
    Arm B - Phase II Investigational TreatmentExperimentalThe maximum safe dose of Imprime PGG in combination with pembrolizumab (as determined in the phase Ib cohort) will be given on Day 1,8, and 15 of each 21 day cycle.
      • MK-3475
      • Imprime PGG

    Eligibility Criteria

    Inclusion Criteria:

    - Subjects with histologically or cytologically confirmed non-small cell lung cancer (NCSLC).

    - Subjects with stage IV non-small cell lung cancer as defined by American Joint Committee on Cancer (AJCC).

    - Subjects without EGFR activating mutation or ALK translocation.

    - Subjects who progressed after first-line platinum-based chemotherapy and who are candidates for second-line therapy.

    - Measurable disease according to RECIST v1.1 obtained by imaging within 28 days prior to study registration.

    - Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 within 28 days prior to study registration.

    - Provided written informed consent and HIPAA authorization for release of personal health information, approved by an Institutional Review Board (IRB).

    NOTE: HIPAA authorization may be included in the informed consent or obtained separately.

    - Women of childbearing potential (WOCP) must not be pregnant or breast-feeding. A negative serum or urine pregnancy test is required within 72 hours of study registration. If the urine test cannot be confirmed as negative, a serum pregnancy test will be required.

    - Women of childbearing potential (WOCP) must be willing to use two effective methods of birth control such as an oral, implantable, injectable, or transdermal hormonal contraceptive, an intrauterine device (IUD), use of a double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream), or total abstinence for the course of the study until 120 days after the last dose of study drug.

    NOTE: Women are considered to be of childbearing potential unless they are postmenopausal (≥45 years of age and has not had menses for greater than 12 consecutive months), surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or not heterosexually active for the duration of the study and at least 120 days after the last dose of study drug.

    - Men who are not surgically sterile (vasectomy) must agree to use an acceptable method of contraception. Male subjects with female sexual partners who are pregnant, possibly pregnant, or who could become pregnant during the study must agree to use condoms from the first dose of study drug through at least 120 days after the last dose of study drug. Total abstinence for the same study period is an acceptable alternative.

    - Willingness and ability to comply with scheduled visits (including geographical distance), treatment plans, laboratory tests, and other study procedures.

    Exclusion Criteria:

    - Surgery within 4 weeks prior to study registration except for minor procedures. NOTE: Hepatic biliary stent placement is allowed. NOTE: Subject must have adequately recovered from the toxicity and/or complications of major surgery prior to study registration, as determined by the treating physician.

    - Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with neurological symptoms must undergo a head CT scan or brain MRI to exclude brain metastasis.

    NOTE: Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to study registration.

    This exception does not include carcinomatous meningitis, which is excluded regardless of clinical stability.

    - Previously received an organ or allogeneic progenitor/stem cell transplant.

    - Received a live vaccine within 30 days prior to the first dose of trial treatment. Examples of live vaccines include, but are not limited to: measles, mumps, rubella, chicken pox, yellow fever, rabies, BCG, and typhoid (oral) vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g. Flu-Mist®) are live attenuated vaccines and are not allowed.

    - History of blood clots, pulmonary embolism, or deep vein thrombosis unless on adequate anticoagulant therapy as determined by the treating investigator (subject must be on stable dose for 2 weeks).

    - Known history of human immunodeficiency virus [(HIV) HIV 1/2 antibodies].

    - Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).

    - Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to study registration.

    - Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs) or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents.

    NOTE: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.

    - Received prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study registration or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events from previously administered agents.

    NOTE: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and can still be considered for the study.

    - Any clinically significant infection defined as any acute viral, bacterial, or fungal infection that requires specific treatment.

    NOTE: Anti-infective treatment must be completed ≥ 7 days prior to study registration.

    - Has history of (non-infectious) pneumonitis that required steroids, evidence of interstitial lung disease or active, non-infectious pneumonitis.

    - Known history of active tuberculosis.

    - Any other severe, uncontrolled medical condition, including uncontrolled diabetes mellitus (defined as a Hemoglobin A1C ≥ 9% in subjects with a prior history of diabetes, 28 days prior to study registration) or unstable congestive heart failure (Stage III-IV of the New York Heart Association Functional Classification)

    - Previous exposure or known allergy to pembrolizumab or any of its excipients

    - Previous exposure or known allergy to Imprime PGG or any of its excipients

    - Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies

    - Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, interfere with protocol compliance, or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for enrollment in this study.

    - Presence of any non-healing wound, fracture, or ulcer within 28 days prior to study registration.

    - Any mental or medical condition that prevents the subject from giving informed consent or participating in the trial.

    - No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, Gleason ≤ grade 7 prostate cancers, or other cancer for which the subject has been disease-free for at least 5 years.

    - Received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).

    - Treatment with any investigational agent within 28 days prior to study registration.

    Maximum Eligible Age:N/A
    Minimum Eligible Age:18 Years
    Eligible Gender:All
    Healthy Volunteers:No

    Primary Outcome Measures

    Measure:Phase Ib: Maximum Tolerated Dose
    Time Frame:From the start of combination treatment until completion of the first cycle of treatment (21 days)
    Safety Issue:
    Description:Phase Ib: Maximum tolerated dose (MTD) for subjects receiving Imprime PGG with pembrolizumab without experiencing dose-limiting toxicity(s) (DLT) per Common Terminology Criteria for Adverse Events (CTCAE) v4

    Secondary Outcome Measures

    Measure:Adverse Effects
    Time Frame:From start of treatment D1 and every treatment visit thereafter (up to 11 months [16 cycles])
    Safety Issue:
    Description:Number of Participants with Adverse Events as a Measure of Safety and Tolerability per Common Terminology Criteria for Adverse Events (CTCAE) v4
    Measure:Clinical Benefit Ratio
    Time Frame:From the start of treatment D1 assessed every 6 weeks +/- 1 week while on study treatment (up to 11 months [16 cycles])
    Safety Issue:
    Description:Clinical Benefit Ratio (complete, partial response, or stable disease) as assessed per RECIST 1.1
    Measure:Overall Survival (OS)
    Time Frame:from the start of the treatment until death from any cause (up to 1 year from start of treatment)
    Safety Issue:
    Description:To determine the overall survival for this patient population at 1 year

    Details

    Phase:Phase 1/Phase 2
    Primary Purpose:Interventional
    Overall Status:Recruiting
    Lead Sponsor:Lawrence Feldman

    Trial Keywords

    • Anti-PD-1
    • Pembrolizumab
    • Imprime PGG
    • MK-3475

    Last Updated

    December 22, 2016